《大行報告》高盛升藥明生物(02269.HK)目標價至117元 上半年業績勝預期
高盛發表研究報告指,藥明生物(02269.HK)近日發盈喜,預期上半年收入將按年增長61%至63%,淨利潤增長35%至37%,非國際會計準則下經調整淨利潤增長58%至60%。
該行預期,中期業績勝預期,可能是由於新冠病毒相關項目的加速交付所推動,反映出公司具有強大的執行能力,盈利增長則主要來自於毛利率及產能利用率提升。
非國際會計準則下淨利潤率預期達到40%,高於去年下半年表現,高盛估計,藥明生物全年業績有望超出早前預期,將2022至2024財年的盈利預測分別上調5.1%、4.6%及4.6%,以利用率提高及人民幣貶值推動毛利率上升,予以「買入」評級,目標價由110.7元升至117元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.